BergenBio Fundamentale Forhold (BGBIO)

[Zydenboy]

Hvorfor hadde sånne problemer med rekruttering under første Accord? Og hvorfor var det ikke quick fix å starte opp Accord 2?

[Twine]

Det sier vel mer om ACCORD enn BergenBio

[BillyP]

https://www.dnb.no/seg-fundamental/fundamentalweb/GetReports.aspx?file=CMP4_166386.pdf&Sid=1-2YAI9

[vulkanen]

Fin den

[danron10]

Bull case: 100 NOK
Base case 68 NOK
Bear case: 30 NOK

Fin at Bear case fremdeles er opp fra dagens kurs.

[Flottesen]

Synes at de forklarte tidlinjen for Covid-19 studiene godt på presentasjonen i går. Disse tingene tar jo alltid lenger tid enn man skulle håpet, men det ser jo ut som første pasient i India kan doseres når som helst nå og innrullering kan jo gå fort når de først er i gang, både i India og UK.

[Skeptikern]

Ah så bgbio er gratis penger mener de, angivelig, hvorfor investerer de ikke selv der da isteden for å fortelle deg om denne gylne muligheten, eller har de ikke lov til å investere slik? Høres mistenkelig ut, for å si det mildt

[Flottesen]

Vanntette skott mellom buy-side og sell-side vet du

[danron10]

du høres neste skeptisk ut, @Skeptikern

[Hfyh]

Mohn som ligger og plukker?

[Realize_1]

Virker ikke varsling på børsmeldinger?

General Meetings - BerGenBio

ViewReleaseInStandardHtml

[diffish]

Jøss. Ekstraordinær generalforsamling i biotek uten at de skal banke gjennom en fullmakt for å kunne kjøre ny emisjon.

Nesten uvant kost.

[TyrionIV]

Den har de allerede banket gjennom ved forrige EGM

[KrissKross]

Er det ikke utskiftninger i styrtet det er snakk om?

[diffish]

@drdr

Noe formening?
Det er i hvert fall ikke klinisk oppdatering og mindre sannsynlig for emisjon, i hvert fall feil tidspunkt mtp at kurset er kunstig presset ned og at de ikke har behov for penger for en god stund!
Nyhet om partnersavtale?

Bare å gå inn på lenken, så ser man at to i styret gir seg, og at de må få inn to nye. Ikke noe mer dramatisk enn det.

[Shattering84]

Ekstraordinært styremøte for å skifte ut noen styremedlemmer

[TekBot]

BerGenBio ASA: Innkalling til Ekstraordinær Generalforsamling

Bergen, Norge, 18 November 2020 – Det blir herved meldt at en ekstraordinær
generalforsamling i BerGenBio ASA vil bli avholdt virtuelt 9 desember 2020
klokken 16.00 (CET).
…

Vis børsmeldingen

Innkalling, påmeldingsskjema og fullmakt er vedlagt dette skrivet. Innkallingen
vil bli sendt til alle registrerte aksjonærer og er tilgengelig på
https://www.bergenbio.com/investors/general-
meetings/ (https://www.bergenbio.com/investors/general-%20meetings/)

Alle aksjonærer oppfordres til å utøve sine stemmerettigheter ved å enten
forhåndsstemme elektronisk gjennom VPS Investortjenester, bruke vedlagte
fullmaktsskjema for å gi fullmakt til styreleder Sveinung Hole (eller personen
han utpeker), eller ved å delta på generalforsamlingen virtuelt.

Virtuelt oppmøte, forhåndsstemme eller fullmakt til den ekstraordinære
generalforsamlingen kan registreres via BerGenBio sin nettside eller VPS
Investortjenester. Alle registrerte aksjonærer vil motta et referansenummer og
en PIN-kode som kreves for registrering via BerGenBio sin nettside.
Referansenummer og PIN-kode vi bli mottatt enten av VPS Investortjenester eller
per post, avhengig av om aksjonæren er registrert som elektronisk bruker.

Vi oppfordrer alle aksjonærer til å registrere seg som elektronisk VPS-bruker
for å spare miljøet.

– SLUTT –

Om BerGenBio ASA

BerGenBio er et klinisk stadium biofarmasøytisk selskap som setter søkelys på å
utvikle transformative medisiner rettet mot AXL som en potensiell hjørnestein i
terapi for aggressive sykdommer, inkludert immunundvikende og
medikamentresistente kreftformer. Selskapets proprietære hovedkandidat,
bemcentinib, er en potensiell førsteklasses selektiv AXL-hemmer i et bredt fase
II onkologisk klinisk utviklingsprgram med fokus på kombinasjons- og
enkeltmiddelterapi i lungekreft, leukemi og COVID-19. Et førsteklasses
funksjonsblokkerende anti-AXL-antistoff gjennomgår klinisk fase I-tester.
Parallelt utvikler BerGenBio en «companion diagnostics» test for å identifisere
de pasientpopulasjonene som mest sannsynlig vil dra nytte av bemcentinib: dette
forventes å legge til rette for mer effektive registreringsforsøk som støtter en
presisjonsmedisinbasert kommersialiseringsstrategi.

BerGenBio har base i Bergen, Norge med et datterselskap i Oxford, Storbritannia.
Selskapet er notert på Oslo Børs (ticker: BGBIO). For mer informasjon,
besøk www.bergenbio.com

Kontakt

Richard Godfrey, administrerende direktør, BerGenBio ASA
+47 917 86 304

Rune Skeie, finansdirektør, BerGenBio ASA
rune.skeie@bergenbio.com
+47 917 86 513

Fremtidsrettede uttalelser

Denne kunngjøringen kan inneholde fremtidsrettede uttalelser, som i seg selv
ikke er historiske fakta, men er basert på forskjellige antagelser, hvorav mange
er basert på ytterligere forutsetninger. Disse forutsetningene er i sin natur
underlagt betydelige kjente og ukjente risikoer, usikkerheter og andre viktige
faktorer. Slike risioer, usikkerheter, betingelser og andre viktige faktorer kan
føre til at faktiske hendelser avviker vesentlig fra forventningene uttrykt
eller underforstått i denne kunngjøringen av slike fremtidsrettede uttalelser.

Denne opplysningen er informasjonspliktig etter verdipapirhandelloven § 5-12.

Kilde

[TekBot]

BERGENBIO CONFIRMS FIRST PATIENT ENROLLED IN PHASE II TRIAL ASSESSING BEMCENTINIB AS A POTENTIAL TREATMENT FOR COVID-19 IN INDIA

Bergen, Norway - 24[th] November 2020: BerGenBio ASA (OSE:BGBIO), a clinical
-stage biopharmaceutical company developing novel, selective AXL kinase
inhibitors for severe unmet medical need, today announces that the first patient
…

Vis børsmeldingen

in India has been enrolled in the company sponsored Phase II clinical trial
(BGBC020), assessing the efficacy and safety of bemcentinib for the treatment of
hospitalised COVID-19 patients.

The Phase II study will recruit 120 hospitalised COVID-19 patients across seven
sites in India and five in South Africa. 60 patients will receive bemcentinib
(as monotherapy or in combination with standard of care medication) and 60
patients in a control group (receiving standard of care treatment only).

The primary endpoint of the trial will be time to clinical improvement of at
least two points (from randomisation) on a nine-point ordinal scale, or live
discharge from the hospital, whichever comes first. The trial protocol will
permit co-administration with other medicines recommended for treatment of COVID
-19, including remdesivir and dexamethasone. A Data Monitoring Committee (DMC)
formed of a group of independent experts external to the study has been
established. The DMC will assess the progress, safety data and, critical
efficacy endpoints of the trial as it proceeds.

Richard Godfrey, Chief Executive Officer of BerGenBio, commented: “We are
pleased to expand the BGBC020 study to patients in India, where incidences of
COVID-19 remain high, following the commencement of dosing in South Africa in
October. There are still no approved therapies for patients hospitalised as a
result of COVID-19 infection and we are keen to continue exploring the profile
of bemcentinib as a potential treatment.”

• END -

About AXL

AXL kinase is a cell membrane receptor and an essential mediator of the
biological mechanisms underlying many life-threatening diseases. In cancer, AXL
suppresses the body’s immune response to tumours and drives cancer treatment
failure across many indications. AXL expression defines a very poor prognosis
subgroup in most cancers. AXL inhibitors, therefore, have potential high value
at the centre of cancer combination therapy, addressing significant unmet
medical needs and multiple high-value market opportunities. Research has also
shown that AXL mediates other aggressive diseases.

About Bemcentinib

Bemcentinib (formerly known as BGB324), is a potentially first-in-class
selective AXL inhibitor in a broad phase II clinical development programme.
Ongoing clinical trials are investigating bemcentinib in multiple solid and
haematological tumours, in combination with current and emerging therapies
(including immunotherapies, targeted therapies and chemotherapy), and as a
single agent. Bemcentinib targets and binds to the intracellular catalytic
kinase domain of AXL receptor tyrosine kinase and inhibits its activity.
Increase in AXL function has been linked to key mechanisms of drug resistance
and immune escape by tumour cells, leading to aggressive metastatic cancers.

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II oncology clinical development
programme focused on combination and single agent therapy in lung cancer,
leukaemia and COVID-19. A first-in-class functional blocking anti-AXL antibody,
tilvestamab, is undergoing phase I clinical testing. In parallel, BerGenBio is
developing companion diagnostic tests to identify patient populations most
likely to benefit from bemcentinib: this is expected to facilitate more
efficient registration trials supporting a precision medicine-based
commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit www.bergenbio.com

Contacts

Richard Godfrey CEO, BerGenBio ASA
+47 917 86 304

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47 917 86 513

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone, Carina Jurs

Consilium Strategic Communications
bergenbio@consilium-comms.com
+44 20 3709 5700

Media Relations in Norway

Jan Petter Stiff, Crux Advisers

stiff@crux.no
+47 995 13 891

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[TekBot]

BERGENBIO TO PRESENT UPDATED CLINICAL DATA AT ASH 2020 MEETING

Bergen, Norway, 30 November 2020 - BerGenBio ASA (OSE:BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical need, is pleased to announce it has been accepted for a
…

Vis børsmeldingen

poster presentation at the 62[nd] Annual American Society of Hematology (ASH)
Meeting, being held virtually from 5-8 December 2020.

The poster will provide an update from the Company’s Phase II study of
bemcentinib (BGBC003) in combination with low dose cytarabine (LDAC) in elderly
relapsed AML patients, and the Phase II BERGAMO trial in patients with high-risk
MDS or AML.

Abstracts have been announced online, and details of the presentation are below.

Title: The Combination of AXL Inhibitor Bemcentinib and Low Dose Cytarabine Is
Well Tolerated and Efficacious in Elderly Relapsed AML Patients: Update from the
Ongoing BGBC003 phase II Trial (NCT02488408)

Date: Sunday, December 6, 2020

Session name: 613. Acute Myeloid Leukemia: Clinical Studies: Poster II

Time: 7.00am - 3.30pm (Pacific Time) / 4.00pm - 12.30am (7[th] Dec) (CET)

Link online to abstract
here (https://ash.confex.com/ash/2020/webprogram/Paper136566.html)

Title: Efficacy and Safety of Bemcentinib in Patients with Myelodysplastic
Syndromes or Acute Myeloid Leukemia Failing Hypomethylating Agents

Date: Saturday, December 5, 2020

Session name: 637 Myelodysplastic Syndromes - Clinical Studies: Poster I
Hematology Disease Topics & Pathways: Diseases, Therapies, MDS, Myeloid
Malignancies, Clinically relevant

Time: 7.00am - 3.30pm (Pacific Time) / 4.00pm - 12.30am (7[th] Dec) (CET)

Link online to abstract
here (https://ash.confex.com/ash/2020/webprogram/Paper140240.html)

The poster will be available at www.bergenbio.com in the section:
Investors/Presentations at the date of the ASH 2020 meeting.

• End -

About AML and the BGBC003 trial

Acute myeloid leukaemia (AML) is a rapidly progressing blood cancer. AML is the
most common form of acute leukaemia in adults, where malignant AML blasts
interfere with the normal functioning of the bone marrow leading to a multitude
of complications like anaemia, infections and bleeding. AML is diagnosed in over
20,000 patients in the US annually and is rapidly lethal if left untreated.
Successful treatment typically requires intensive therapy or bone marrow
transplantation, and relapse and resistance are common. Consequently, there is
an urgent need for effective novel therapies in relapsed/refractory patients,
particularly those that are ineligible for intensive therapy or bone marrow
transplant.

The BGBC003 trial is a phase Ib/II multi-centre open label study of bemcentinib
in combination with cytarabine (part B2) and decitabine (part B3) in patients
with AML who are unsuitable for intensive chemotherapy as a result of advanced
age or existing comorbidities. Up to 28 patients will be enrolled at centres in
the US, Norway, Germany and Italy.

For more information please access trial NCT02488408 at www.clinicaltrials.gov.

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II clinical development
programme focused on combination and single agent therapy in lung cancer,
leukaemia and COVID-19. A first-in-class functional blocking anti-AXL antibody,
tilvestamab, is undergoing phase I clinical testing. In parallel, BerGenBio is
developing a companion diagnostic test to identify patient populations most
likely to benefit from bemcentinib: this is expected to facilitate more
efficient registration trials supporting a precision medicine-based
commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit www.bergenbio.com

Contacts

Richard Godfrey CEO, BerGenBio ASA
+47 917 86 304

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47 917 86 513

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone, Carina Jurs

Consilium Strategic Communications
bergenbio@consilium-comms.com
+44 20 3709 5700

Media Relations in Norway

Jan Petter Stiff, Crux Advisersstiff@crux.no
+47 995 13 891

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[Mykle]

Er ikke dette det samme som ble børsmeldt 4. November? Abstrakt og tittel ble jo meldt da.